Patrick Decker elected to CRH Board of Directors

Richie Boucher Independent Chairman and Non-management Director CRH
Richie Boucher Independent Chairman and Non-management Director - CRH
0Comments

CRH has announced the election of Patrick Decker to its Board of Directors, effective October 1, 2025. Decker, age 60, brings a background in leading global organizations within the industrial and water technology sectors.

“We are delighted to welcome Patrick to our Board of Directors,” said Richie Boucher, CRH Chairman. “With his extensive experience in leading global organizations and his deep understanding of the industrial and water technology sectors, Patrick brings invaluable insights and expertise to our team. His proven track record of driving innovation and achieving strategic goals will be instrumental as we continue to execute our vision and deliver value to our shareholders.”

Decker is the retired president and CEO of Xylem Inc., where he served from March 2014 through December 2023. Before joining Xylem, he was president and CEO at Harsco Corporation between 2012 and 2014. He also held various leadership roles at Tyco from 2003 until 2012, including serving as president of Tyco Flow Control. Earlier in his career, Decker worked for Bristol-Myers Squibb in financial and operational positions focused on Latin America and Asia, after starting out with Price Waterhouse.

Currently, Decker serves on the board of Johnson Controls International, which operates in over 150 countries providing smart building solutions. He is also a board member at Mass Eye and Ear, a Harvard-affiliated hospital specializing in hearing and vision research.

Decker holds a Bachelor of Science degree in Accounting and Finance from Indiana University and is a member of the Global Dean’s Council for Kelley School of Business at Indiana University.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.